Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Facial implants

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Facial implants. Displaying page 1 of 1.
    EudraCT Number: 2015-004789-27 Sponsor Protocol Number: 21.November.2015 Start Date*: 2016-03-03
    Sponsor Name:Bispebjerg Hospital
    Full Title: Topical brimonidine to reduce post-inflammatory response after IPL- treatment and effect on IPL-efficacy in patients with facial telangiectasias
    Medical condition: Inflammation after IPL-treatment in patients with facial telangiectasias
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10043189 Telangiectasia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-018024-15 Sponsor Protocol Number: CUV100 Start Date*: 2010-05-27
    Sponsor Name:Clinuvel Pharmaceuticals Limited
    Full Title: A Phase II, Randomised, Open Label Pilot Study to Evaluate the Efficacy and Safety of Two Dosage Regimens of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Mild to Moderate Acne...
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000519 Acne vulgaris LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020796-24 Sponsor Protocol Number: DPSI-Acanya-P4-03 / 300108BS Start Date*: 2010-10-13
    Sponsor Name:Dow Pharmaceutical Sciences, Inc
    Full Title: A multi-center, randomized, observer-blind trial to compare the irritant potential of the two topical acne formulations Acanya® Gel and Epiduo® Gel on acneic skin in a split-face assessment during ...
    Medical condition: Subjects with facial acne
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000749-21 Sponsor Protocol Number: 4.20 Start Date*: 2016-03-14
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Botulinumtoxin A for emotional stabilization in borderline personality disorder
    Medical condition: Borderline personality disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015014-22 Sponsor Protocol Number: FFS113203 Start Date*: 2009-12-04
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray (FFNS) 110 mcg, administe...
    Medical condition: Uncomplicated acute rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10052106 Rhinosinusitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) NL (Completed) NO (Ongoing) SE (Completed) ES (Completed) DE (Completed) PL (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-003623-35 Sponsor Protocol Number: CRS-02 Start Date*: 2012-09-14
    Sponsor Name:Bionorica SE
    Full Title: A multicentre, randomized, double-blind, placebo-controlled, parallel group study to assess efficacy and safety of two dosages of a herbal medicinal product (dry extract BNO 1016) in patients with ...
    Medical condition: Chronic Rhinosinusitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) DE (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002418-11 Sponsor Protocol Number: RH01913 Start Date*: 2013-08-12
    Sponsor Name:GlaxoSmithKline Consumer Healthcare
    Full Title: A study to evaluate the effect of a 67% Sodium Bicarbonate containing toothpaste on Chlorhexidine Digluconate tooth staining
    Medical condition: Tooth discolouration (a labelled undesirable effect of Corsodyl 0.2% mouthwash)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10044032 Tooth discolouration PT
    14.1 10021881 - Infections and infestations 10018292 Gingivitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2015-001952-31 Sponsor Protocol Number: CRS-03 Start Date*: 2016-04-14
    Sponsor Name:Bionorica SE
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial to assess efficacy and safety of the herbal medicinal product Sinupret extract coated tablets in patients ...
    Medical condition: Chronic rhinosinusitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004862 10052106 Rhinosinusitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005501-22 Sponsor Protocol Number: LEO 80190-O23 Start Date*: 2008-04-22
    Sponsor Name:LEO Pharma A/S
    Full Title: Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas
    Medical condition: Psoriasis vulgaris on the face and on the intertriginous areas. The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldnes...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004765-90 Sponsor Protocol Number: DFD03-CD-004 Start Date*: 2016-07-13
    Sponsor Name:Dr. Reddy’s Laboratories, Ltd
    Full Title: A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
    Medical condition: Acne vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001575-23 Sponsor Protocol Number: 201884 Start Date*: 2017-09-21
    Sponsor Name:GlaxoSmithKline KK
    Full Title: Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese Subjects.
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018399 10000519 Acne vulgaris LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-001179-39 Sponsor Protocol Number: 2005108 Start Date*: 2006-10-11
    Sponsor Name:Procter & Gamble Pharmaceuticals
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Wome...
    Medical condition: Hypoactive sexual desire disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10020933 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005486-23 Sponsor Protocol Number: DFD04-CD-002 Start Date*: 2016-04-13
    Sponsor Name:Dr. Reddy's Laboratories, Ltd
    Full Title: A Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of DFD-04 (itraconazole) Ointment, 5% in Patients with Inflammator...
    Medical condition: papulopustular Rosacea (patients with inflammatory lesions of rosacea)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004543-40 Sponsor Protocol Number: ONC-2015-001/ML29968 Start Date*: 2016-09-20
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: A SINGLE ARM, PHASE II, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF VISMODEGIB AND RADIOTHERAPY IN PATIENTS WITH HIGH RISK OR LOCALLY ADVANCED BASAL CELL CARCINOMA NOT AMENABLE TO RADICA...
    Medical condition: HIGH RISK OR LOCALLY ADVANCED BASAL CELL CARCINOMA NOT AMENABLE TO RADICAL SURGERY
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000950-78 Sponsor Protocol Number: CB-03-01/35 Start Date*: 2019-08-20
    Sponsor Name:Cassiopea S.p.A.
    Full Title: A Phase 2, multicenter, prospective, randomized, double-blind, Minoxidil and vehicle controlled, dose-ranging study to evaluate the efficacy and safety of CB-03-01 (Cortexolone 17α-propionate) solu...
    Medical condition: Female Androgenic Alopecia (AGA) is scalp hair loss that occurs due to an underlying susceptibility of hair follicles to androgenic miniaturization. In the hair follicle, testosterone is converted ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10068558 Androgenic alopecia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002257-37 Sponsor Protocol Number: UC-0105/1611 Start Date*: 2017-02-10
    Sponsor Name:UNICANCER
    Full Title: Secured access to nivolumab for adult patients with selected rare cancer types
    Medical condition: Unresectable locally advanced or metastatic, non-clear cell renal cell carcinoma, rare head and neck cancer, rare skin cancer, MSI-nonCRC or penile cancer, which is resistant or refractory to stand...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002613-17 Sponsor Protocol Number: SONIBEC Start Date*: 2020-10-13
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: A phase II, open-label study improving compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (BCC) – ...
    Medical condition: Adult patients with locally advanced BCC, not amenable to surgical treatment and who obtained a complete response (CR) to Hedgehog inhibitors as defined by RECIST 1.1 and dermoscopic exam regardles...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064679 Basal cell carcinoma of skin in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002193-31 Sponsor Protocol Number: CRN00808-05 Start Date*: 2020-02-19
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRN00808 IN SUBJECTS WITH ACROMEGALY (ACROBAT ADVANCE)
    Medical condition: Acromegaly is typically caused by a growth hormone (GH) secreting tumor in the pituitary. Excess GH secretion results in excess secretion of insulin-like growth factor-1 (IGF-1) from the liver, whi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Completed) GR (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003806-33 Sponsor Protocol Number: AEGR-733-020 Start Date*: 2016-06-30
    Sponsor Name:Aegerion Pharmaceuticals Inc.
    Full Title: A Phase 3, Single-arm, Open-label, International, Multi-center Study to Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia on Stable ...
    Medical condition: Homozygous familial hypercholesterolemia (HoFH).
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000195-34 Sponsor Protocol Number: MO25616 Start Date*: 2011-06-21
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A single arm, open-label, phase II, multicentre study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC).
    Medical condition: Locally advanced or metastatic basal cell carcinoma (BCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) DE (Completed) BG (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) NL (Completed) SI (Completed) DK (Completed) HU (Completed) CZ (Completed) GR (Completed) SK (Completed) IE (Completed) PT (Completed) PL (Completed) NO (Completed) LT (Completed) FI (Completed) EE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 02:25:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA